Machine learning-based prediction model for 30-day readmission risk in elderly patients with type 2 diabetes mellitus and heart failure: a retrospective cohort study with SHAP interpretability analysis

基于机器学习的预测模型用于预测老年2型糖尿病合并心力衰竭患者30天再入院风险:一项回顾性队列研究及SHAP可解释性分析

阅读:1

Abstract

OBJECTIVE: Among elderly populations with concurrent type 2 diabetes mellitus (T2DM) and heart failure (HF), 30-day hospital readmission rates range 10%-25%. Conventional risk evaluation instruments show restricted predictive performance (AUC < 0.70) in this multimorbid group. This research aimed to construct and verify an artificial intelligence-based algorithm for assessing 30-day readmission probability in elderly T2DM-HF patients. METHODS: This retrospective cohort study included 870 participants ≥65 years with T2DM and HF (January 2020-December 2023), randomly divided into training (n = 609, 70%) and validation (n = 261, 30%) cohorts. Variable selection utilized Least Absolute Shrinkage and Selection Operator with ten-fold cross-validation. Eight machine learning algorithms were evaluated: logistic regression, random forest, gradient boosting machines, support vector machines, neural networks, convolutional neural networks, AdaBoost, and stacking ensemble. Model interpretability was enhanced using SHapley Additive exPlanations analysis. RESULTS: Overall 30-day readmission rate was 12.4% (108/870 patients). The Stacking Ensemble model achieved superior performance with AUC 0.867 (95% CI: 0.830-0.904), accuracy 79.4%, sensitivity 74.9%, and specificity 84.0%. Fourteen key predictors were identified, with C-reactive protein, estimated glomerular filtration rate, and B-type natriuretic peptide as most influential factors. CONCLUSION: This study developed a high-performing, interpretable machine learning model for predicting 30-day readmission risk, providing a valuable clinical decision-making tool.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。